Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay

International Journal of Antimicrobial Agents

Volumn 37, Issue 3, 2011, Pages 244-247

  Pournaras, Spyros ^a   Vrioni, Georgia ^b   Neou, Evangelia ^a   Dendrinos, John ^b   Dimitroulia, Evangelia ^b   Poulou, Aggeliki ^c   Tsakris, Athanassios ^b  

^a UNIVERSITY OF THESSALY   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c General District Hospital of Serres   (Greece)

Author keywords

Bactericidal; Bacteriostatic; Class A carbapenemase; Colistin; KPC; Meropenem; Synergistic; Tigecycline; Time kill

Indexed keywords

CARBAPENEMASE; COLISTIN; MEROPENEM; TIGECYCLINE;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; DRUG CHOICE; DRUG POTENTIATION; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SERRATIA MARCESCENS;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; COLISTIN; DRUG COMBINATIONS; DRUG RESISTANCE, BACTERIAL; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; ESCHERICHIA COLI; HUMANS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; SERRATIA MARCESCENS; THIENAMYCINS;

EID: 79951957668     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.10.031     Document Type: Article

References (15)

1. S. Bratu, D. Landman, R. Haag, R. Recco, A. Eramo, and M. Alam Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium Arch Intern Med 165 2005 1430 1435 (Pubitemid 40973427)
2. P. Nordmann, G. Cuzon, and T. Naas The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria Lancet Infect Dis 9 2009 228 236
3. A. Tsakris, I. Kristo, A. Poulou, F. Markou, A. Ikonomidis, and S. Pournaras First occurrence of KPC-2-possessing Klebsiella pneumoniae in a Greek hospital and recommendation for detection with boronic acid disc tests J Antimicrob Chemother 62 2008 1257 1260
4. E.B. Hirsch, and V.H. Tam Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection J Antimicrob Chemother 65 2010 1119 1125
5. S. Pournaras, E. Protonotariou, E. Voulgari, I. Kristo, E. Dimitroulia, and D. Vitti Clonal spread of KPC-2 carbapenemase-producing Klebsiella pneumoniae in Greece J Antimicrob Chemother 64 2009 348 352
6. M. Castanheira, H.S. Sader, L.M. Deshpande, T.R. Fritsche, and R.N. Jones Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-β-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program Antimicrob Agents Chemother 52 2008 570 573 (Pubitemid 351170830)
7. S. Bratu, P. Tolaney, U. Karumudi, J. Quale, M. Mooty, and S. Nichani Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents J Antimicrob Chemother 56 2005 128 132 (Pubitemid 41418346)
8. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twentieth informational supplement. June 2010 Update. Document M100-S20U. Wayne, PA: CLSI; 2010.
9. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters, version 1.0. Basel, Switzerland: EUCAST; 2009.
10. J. Cobo, M.I. Morosini, V. Pintado, M. Tato, N. Samaranch, and F. Baquero Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 β-lactamase-producing Klebsiella pneumoniae epidemic clone Diagn Microbiol Infect Dis 60 2008 319 322 (Pubitemid 351255574)
11. C. Vidaillac, S.N. Leonard, H.S. Sader, R.N. Jones, and M.J. Rybak In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant Gram-negative pathogens, including β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa Antimicrob Agents Chemother 53 2009 2360 2366
12. G.A. Pankey, and D.S. Ashcraft In vitro antibacterial activity of tigecycline against resistant Gram-negative bacilli and enterococci by time-kill assay Diagn Microbiol Infect Dis 64 2009 300 304
13. G.G. Zhanel, P.J. Baudry, F. Tailor, L. Cox, D.J. Hoban, and J.A. Karlowsky Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum β-lactamases, AmpC β-lactamases and reduced susceptibility to carbapenems using an in vitro model J Antimicrob Chemother 64 2009 824 828
14. S.A. Weisenberg, D.J. Morgan, R. Espinal-Witter, and D.H. Larone Clinical outcomes of patients with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae after treatment with imipenem or meropenem Diagn Microbiol Infect Dis 64 2009 233 235
15. J.M. Entenza, and P. Moreillon Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies Int J Antimicrob Agents 34 8 2009 e1 e9